Journal Article

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa

Obasa, Adetayo Emmanuel, Jacobs, Graeme Brendon, Neogi, Ujjwal, Ambikan, Anoop T., Gupta, Soham

2021

Overview

Background HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in South Africa. This study entailed an evaluation of HIV-1 drug resistance-associated mutations (RAMs) among minor viral populations through high-throughput sequencing genotypic resistance testing (HTS-GRT) in patients on the South African national second-line cART regimen receiving bPIs. Methods During 2017 and 2018, 67 patient samples were sequenced using high-throughput sequencing (HTS), of which 56 samples were included in the final analysis because the patient’s treatment regimen was available at the time of sampling. All patients were receiving bPIs as part of their cART. Viral RNA was extracted, and complete pol genes were amplified and sequenced using Illumina HiSeq2500, followed by bioinformatics analysis to quantify the RAMs according to the Stanford HIV Drug Resistance Database. Results Statistically significantly higher PI RAMs were observed in minor viral quasispecies (25%; 14/56) compared to non-nucleoside reverse transcriptase inhibitors (9%; 5/56; p  = 0.042) and integrase inhibitor RAM (4%; 2/56; p  = 0.002). The majority of the drug resistance mutations in the minor viral quasispecies were observed in the V82A mutation ( n  = 13) in protease and K65R ( n  = 5), K103N ( n  = 7) and M184V (n = 5) in reverse transcriptase. Conclusions HTS-GRT improved the identification of PI and reverse transcriptase inhibitor (RTI) RAMs in second-line cART patients from South Africa compared to the conventional GRT with ≥20% used in Sanger-based sequencing. Several RTI RAMs, such as K65R, M184V or K103N and PI RAM V82A, were identified in < 20% of the population. Deep sequencing could be of greater value in detecting acquired resistance mutations early.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Anti-Retroviral Agents - therapeutic use / Antiretroviral agents / Antiretroviral drugs / Antiretroviral therapy / Bioinformatics / Boosted protease inhibitors (bPIs) / Drug resistance / Drug Resistance, Viral - drug effects / Drug Resistance, Viral - genetics / Ethics / Genes, pol - genetics / Genetic aspects / Genotype / GLP-1 receptor agonists / High-throughput sequencing (HTS) / HIV / HIV Infections - drug therapy / HIV Infections - virology / HIV Protease Inhibitors - therapeutic use / HIV-1 - drug effects / HIV-1 - genetics / HIV-1 - isolation & purification / Human immunodeficiency virus / Humans / Infectious Diseases / Integrase / Internal Medicine / Laboratories / Medical Microbiology / Medical research / Medicine / Medicine & Public Health / Mutation / Next-generation sequencing / Non-nucleoside reverse transcriptase inhibitors / Non-nucleoside reverse transcriptase inhibitors (NNRTIs) / Nucleoside reverse transcriptase inhibitors (NRTIs) / Parasitology / Patient outcomes / Patients / Protease / Protease inhibitors / Proteinase inhibitors / Quasispecies - drug effects / Quasispecies - genetics / Research Article / RNA, Viral - genetics / RNA-directed DNA polymerase / Sexually transmitted diseases / South Africa - epidemiology / Statistical methods / Tropical Medicine